Dallas PE firm bets on company benefitting from drug cost plan

Dallas private equity firm Ancor Capital Partners acquired a company in a growing niche of the health care industry that finds itself at the center of the fight over soaring pharmaceutical costs. And a recent plan released by the Trump administration earlier this year to lower drug prices may give the investment an even bigger boost. “As drug costs continue to increase, there is an increasing burden on pharmaceutical companies to justify pricing, and decision makers expect increasingly sophisticated…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news